Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CF PHARMTECH
长|风|药|业

CF PharmTech, Inc.
長風藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2652)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026; ELECTION OF THE FOURTH SESSION OF THE BOARD; AND ELECTION OF THE FOURTH SESSION OF THE SUPERVISORY COMMITTEE

Reference is made to the circular of CF PharmTech, Inc. (the "**Company**") dated June 2, 2026 (the "**Circular**") incorporating, amongst others, the notice (the "**Notice**") of annual general meeting of the Company (the "**AGM**"). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

At the AGM held on June 26, 2026, all the proposed ordinary resolutions and special resolutions as set out in the Notice were taken by poll.

As at the date of the AGM, the total number of issued Shares of the Company (excluding treasury shares) was 410,581,387 Shares, comprising 109,754,801 domestic shares and 300,826,586 H Shares. The Company held 1,397,000 treasury shares, and no voting rights were exercised in respect of such treasury shares at the AGM. The Company had no repurchased Shares pending cancellation as at the date of the AGM. As at the date of the AGM, 2,960,500 H Shares, which had been purchased on the market, were reserved under the H Share Award Scheme. In accordance with Rule 17.05A of the Listing Rules, the voting rights attached to such H Shares are required not to be exercised, and were not exercised, on any resolution at the AGM which requires Shareholders' approval under the Listing Rules. Accordingly, the total number of Shares entitling the holders to attend and vote for, against or abstain from voting on the resolutions proposed at the AGM was 407,620,887 Shares. There were no Shares entitling the Shareholders to attend and vote only against the resolutions at the AGM.

ATTENDANCE AT THE AGM

The Board comprises 10 members, all of whom attended the AGM in person or by electronic means.

The Shareholders or authorized proxies of the Shareholders attending the AGM held an aggregate of 132,599,134 Shares with voting rights in aggregate, representing approximately 32.30% of the total issued Shares of the Company (excluding treasury shares).

Voting at the AGM was conducted by way of poll. The AGM was convened and held in accordance with the applicable PRC laws and regulations, the Listing Rules and the Articles of Association.

Save as disclosed above, to the best knowledge, information and belief of the Company: (i) there were no restrictions on any Shareholders to cast votes on any of the proposed resolutions at the AGM; (ii) no Shareholder was required under the Listing Rules to abstain from voting on any of the proposed resolutions at the AGM; (iii) there were no Shares entitling the holders to attend and abstain from voting in favor of any of the proposed resolutions at the AGM as required by Rule 13.40 of the Listing Rules; (iv) there were no Shares that were actually voted but were excluded from the calculation of the poll results at the AGM; and (v) no party stated any intention in the Circular to vote against or abstain from voting on any of the proposed resolutions.

Computershare Hong Kong Investor Services Limited, the H Share registrar of the Company, acted as the scrutineer for the vote-taking at the AGM.

POLL RESULTS OF THE AGM

All resolutions proposed at the AGM were taken by poll. The poll results were as follows:

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes cast		
		For	Against	Abstain
1.	To consider and approve the audited consolidated financial statements of the Company for the year ended December 31, 2025.	132,596,634 100.00%	– 0.00%	2,500 0.00%
2.	To consider and approve the annual report of the Company for the year ended December 31, 2025.	132,596,634 100.00%	– 0.00%	2,500 0.00%
3.	3.1 To consider and approve the election of Dr. LIANG Bill Wenqing as executive Director for the Fourth Session of the Board.	132,596,634 100.00%	– 0.00%	2,500 0.00%
	3.2 To consider and approve the election of Dr. LI LI BOVET as executive Director for the Fourth Session of the Board.	132,596,634 100.00%	– 0.00%	2,500 0.00%
	3.3 To consider and approve the election of Dr. LI Qi as executive Director for the Fourth Session of the Board.	132,596,634 100.00%	– 0.00%	2,500 0.00%
	3.4 To consider and approve the election of Ms. ZHU Yuyu as executive Director for the Fourth Session of the Board.	132,596,634 100.00%	– 0.00%	2,500 0.00%
	3.5 To consider and approve the election of Ms. ZHANG Jingjing as executive Director for the Fourth Session of the Board.	132,596,634 100.00%	– 0.00%	2,500 0.00%
	3.6 To consider and approve the election of Mr. CAI Lei as non-executive Director for the Fourth Session of the Board.	132,596,634 100.00%	– 0.00%	2,500 0.00%

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes cast		
		For	Against	Abstain
	3.7 To consider and approve the election of Dr. YI Hua as non-executive Director for the Fourth Session of the Board.	132,596,634 100.00%	– 0.00%	2,500 0.00%
	3.8 To consider and approve the election of Dr. JIN Jian as independent non-executive Director for the Fourth Session of the Board.	132,596,634 100.00%	– 0.00%	2,500 0.00%
	3.9 To consider and approve the election of Ms. WANG Lijuan as independent non-executive Director for the Fourth Session of the Board.	132,596,634 100.00%	– 0.00%	2,500 0.00%
	3.10 To consider and approve the election of Mr. WEI Shirong as independent non-executive Director for the Fourth Session of the Board.	132,596,634 100.00%	– 0.00%	2,500 0.00%
	3.11 To consider and approve the election of Mr. IP Wang Hoi as independent non-executive Director for the Fourth Session of the Board.	132,596,634 100.00%	– 0.00%	2,500 0.00%
4.	4.1 To consider and approve the election of Ms. CHENG Xiangfeng as Supervisor for the Fourth Session of the Supervisory Committee.	132,596,634 100.00%	– 0.00%	2,500 0.00%
	4.2 To consider and approve the election of Ms. KUAI Jingjing as Supervisor for the Fourth Session of the Supervisory Committee.	132,596,634 100.00%	– 0.00%	2,500 0.00%
	4.3 To consider and approve the election of Mr. ZHENG Yao as Supervisor for the Fourth Session of the Supervisory Committee.	132,596,634 100.00%	– 0.00%	2,500 0.00%
5.	To consider and approve the re-appointment of Ernst & Young as the auditor of the Company for a term until the conclusion of the next annual general meeting of the Company and to authorise the Board to determine its remuneration.	132,596,634 100.00%	– 0.00%	2,500 0.00%
6.	To consider and approve the proposed amendments to the H Share Award Scheme to expand the scope of eligible participants to include service providers, and to authorize the Board and/or its delegatee to implement the amended H Share Award Scheme.	132,596,634 100.00%	– 0.00%	2,500 0.00%

SPECIAL RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes cast		
		For	Against	Abstain
7.	To consider and approve the proposal regarding the grant of a general mandate to the Board to allot, issue and/or deal with (including any sale or transfer of treasury shares, if permitted under the Listing Rules) additional H shares of the Company not exceeding 20% of the total number of H shares of the Company in issue (excluding treasury shares), and to authorise the Board to make such amendments as it deems appropriate to the provisions of the articles of association of the Company, so as to reflect the new capital structure upon additional allotment and issuance of shares pursuant to such mandate.	132,596,634 100.00%	– 0.00%	2,500 0.00%
8.	To grant a share repurchase mandate to the Board to repurchase shares of the Company not exceeding 10% of the total number of H shares of the Company in issue (excluding treasury shares).	132,596,634 100.00%	– 0.00%	2,500 0.00%

* *Percentages in the table above have been rounded to two decimal places.*

The full text of the abovementioned resolutions proposed at the AGM was set out in the Circular.

As more than 50% of the votes were cast in favour of each of the resolutions numbered 1 to 6 above, all of the above ordinary resolutions were duly passed at the AGM. As not less than 75% of the votes were cast in favour of each of the resolutions numbered 7 to 8 above, all of the above special resolutions were duly passed at the AGM.

ELECTION OF THE FOURTH SESSION OF THE BOARD

At the AGM, (1) Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi and Ms. ZHU Yuyu were re-elected as executive Directors of the fourth session of the Board; (2) Ms. ZHANG Jingjing was elected as an executive Director of the fourth session of the Board; (3) Mr. CAI Lei and Dr. YI Hua were re-elected as non-executive Directors of the fourth session of the Board; and (4) Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi were re-elected as independent non-executive Directors of the fourth session of the Board.

The term of office of each Director of the fourth session of the Board shall become effective on June 26, 2026. For the biographical details of the Directors of the fourth session of the Board and other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules, please refer to the Circular. As at the date of this announcement, such information remained unchanged.

ELECTION OF THE FOURTH SESSION OF THE SUPERVISORY COMMITTEE

At the AGM, (1) Ms. CHENG Xiangfeng and Ms. KUAI Jingjing were re-elected as Supervisors of the fourth session of the Supervisory Committee; and (2) Mr. ZHENG Yao was elected as a Supervisor of the fourth session of the Supervisory Committee.

The term of office of each Supervisor of the fourth session of the Supervisory Committee shall become effective on June 26, 2026. For the biographical details of the Supervisors of the fourth session of the Supervisory Committee and other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules, please refer to the Circular. As at the date of this announcement, such information remained unchanged.

Ms. ZHANG Jingjing, a Supervisor of the third session of the Supervisory Committee, resigned as a Supervisor with effect from May 29, 2026 and was elected at the AGM as an executive Director of the fourth session of the Board. She will therefore cease to discharge her duties as a Supervisor with effect from June 26, 2026.

By order of the Board
CF PharmTech, Inc.
長風藥業股份有限公司
Dr. LIANG Bill Wenqing
Chairperson, Executive Director and Chief Executive Officer

Hong Kong, June 26, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bill Wenqing, Dr. LI LI BOVET, Dr. LI Qi, Ms. ZHU Yuyu and Ms. ZHANG Jingjing as executive Directors, Mr. CAI Lei and Dr. YI Hua as non-executive Directors, and Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong and Mr. IP Wang Hoi as independent non-executive Directors.